Texas Attorney General Ken Paxton has filed a lawsuit against the makers of Tylenol, alleging the company misrepresented the drug’s safety during pregnancy. The suit claims Johnson & Johnson and its subsidiary, McNeil Consumer Healthcare, failed to adequately warn consumers about a potential link between acetaminophen, the active ingredient in Tylenol, and an increased risk of neurodevelopmental disorders such as ADHD and autism in children.

The lawsuit centers on accusations that the companies were aware of possible risks associated with acetaminophen use during pregnancy but did not sufficiently inform consumers. Paxton cited several studies suggesting a correlation between prenatal exposure to acetaminophen and an elevated risk of neurodevelopmental issues in children.

Despite this evidence, the lawsuit alleges that the companies continued to market Tylenol as a safe option for pregnant women without providing clear warnings. The state of Texas is seeking monetary damages and an injunction to prevent further deceptive marketing practices.

If successful, this lawsuit could have major implications for the pharmaceutical industry. It could set a precedent for holding companies accountable for failing to warn consumers about potential health risks, particularly for vulnerable populations such as pregnant women.

The case could also lead to greater scrutiny of other over-the-counter medications and their safety profiles during pregnancy. Future labeling requirements and corporate transparency standards may be influenced by its outcome.

The lawsuit highlights a growing debate about the balance between medication use during pregnancy and potential risks to child development. It underscores the need for clearer communication, stronger oversight and continued research into the long-term effects of commonly used drugs.